Market Place
Sourcing Support
Sirnaomics Subscribed For 17,527,696 Subscription Shares
04 Oct 2024 //
PR NEWSWIRE
Sirnaomics Shows Novel MOA Of siRNA For Fat Reduction
19 Sep 2024 //
PR NEWSWIRE
Sirnaomics Partners With Gore Range Capital For Aesthetic Medicine JV
31 Jul 2024 //
PR NEWSWIRE
Sirnaomics Completes IND-Enabling Studies For STP125G In Cardiovascular Care
11 Jul 2024 //
PR NEWSWIRE
Sirnaomics Completes STP707 Ph I Study With Strong Safety For Pancreatic Cancer
28 Jun 2024 //
PR NEWSWIRE
Sirnaomics Demonstrates Antitumor Activity Of Novel Conjugate
12 Jun 2024 //
PR NEWSWIRE
Sirnaomics Announces 2023 Annual Results
28 Mar 2024 //
PR NEWSWIRE
Sirnaomics will Present its Innovative Dual-Targeted GalNAc muRNA Programs
12 Mar 2024 //
PR NEWSWIRE
Sirnaomics to Present Latest Developments of STP705 for Focal Fat Reduction
05 Feb 2024 //
PR NEWSWIRE
Sirnaomics Publishes Novel Mechanism of Action of RNAi Cancer Therapeutic STP707
24 Jan 2024 //
PR NEWSWIRE
Sirnaomics Promotes Francois Lebel, M.D. to Chief Medical Officer
01 Dec 2023 //
PR NEWSWIRE
Sirnaomics Presents Positive Clinical Data of STP705 for Focal Fat Reduction
01 Nov 2023 //
PR NEWSWIRE
Sirnaomics Announces Successful Ph I Clinical Study of RNAi Therapeutic STP707
30 Aug 2023 //
PR NEWSWIRE
Sirnaomics Appoints Dr. Francois Lebel as Senior Vice President
27 Jul 2023 //
PR NEWSWIRE
Sirnaomics advances isSCC candidate into late-stage clinical development
20 Jun 2023 //
PHARMAFILE
Sirnaomics gears up for Phase III isSCC trial
20 Jun 2023 //
CLINICAL TRIALS ARENA
Sirnaomics Advances STP705 for SCC In Situ into Late-Stage Clinical DevP
19 Jun 2023 //
PR NEWSWIRE
Sirnaomics to Present Developments on GalAhead Therapeutic Platform
13 Jun 2023 //
PR NEWSWIRE
Sirnaomics Reports Interim Results of STP705 Phase I Clinical Study
05 Jun 2023 //
PR NEWSWIRE
Sirnaomics Dosed First Patient in PI Study of RNAi Therapeutic STP122G
01 Jun 2023 //
PR NEWSWIRE
Sirnaomics Announces 2022 Annual Results
28 Mar 2023 //
PR NEWSWIRE
Sirnaomics to Present Latest Developments in Polypeptide Nanoparticle Platform
20 Mar 2023 //
PR NEWSWIRE
Sirnaomics Accelerates Clinical Development of STP705
01 Feb 2023 //
PR NEWSWIRE
Sirnaomics Announces Interim Data from Ph I Trial of RNAi Therapeutic STP707
20 Dec 2022 //
PR NEWSWIRE
Inspira™ Technologies Begins Manufacturing of the ALICE™ CPB Device
20 Dec 2022 //
PR NEWSWIRE
Sirnaomics reports data from Phase IIb squamous cell carcinoma trial
15 Dec 2022 //
CLINICALTRIALSARENA
Sirnaomics Announces Positive Data from Phase IIb Clinical Trial of STP705
14 Dec 2022 //
PRNEWSWIRE
Sirnaomics Director Dr. Xiaochang Dai to Deliver Keynote Speech at BIOHK2022
13 Dec 2022 //
PRNEWSWIRE
Sirnaomics Doses the First Patient in Phase I Trial of RNAi Therapeutic STP705
07 Nov 2022 //
PRNEWSWIRE
Sirnaomics to Present Developments on siRNA Therapeutics
20 Sep 2022 //
PRNEWSWIRE
Sirnaomics to Present at 3rd Annual Jefferies Asia Forum
06 Sep 2022 //
PRNEWSWIRE
Sirnaomics Advances GalAhead-Based Drug Candidates Focused on Complement
30 Aug 2022 //
CONTRACTPHARMA
Sirnaomics Achieves 100% Complete Response in Phase II Clinical Trial of STP705
29 Aug 2022 //
PRNEWSWIRE
Sirnaomics’ skin cancer therapy offers complete response in Phase II trial
29 Aug 2022 //
CLINICALTRIALSARENA
Sirnaomics Advances GalAhead(TM)-Based RNAi Therapeutics
26 Aug 2022 //
PRNEWSWIRE
Sirnaomics Begins Dosing in PI/II Study of RNAi Therapeutic STP705
18 Aug 2022 //
PRNEWSWIRE
Sirnaomics Develops PDoV(TM) Designed for an Enhanced GalNAc Delivery Platform
16 Aug 2022 //
PRNEWSWIRE
Sirnaomics Receives IND Clearance from Taiwan MHW for PI Study of STP705
25 Jul 2022 //
PRNEWSWIRE
Sirnaomics to Present the Latest Developments of Dual-Targeted RNAi Therapeutics
21 Jun 2022 //
PRNEWSWIRE
Sirnaomics Announces Publication of STP705 Study Results for Treatment of isSCC
16 Jun 2022 //
BIOSPACE
Sirnaomics Begins PI Trial of RNAi Therapeutic STP705 for Cosmetology Treatment
30 May 2022 //
PRNEWSWIRE
Sirnaomics presents study results & development strategy for RNA Therapeutics
20 May 2022 //
ASIAONE
Sirnaomics to Present GalNAc-Based Liver-Targeting Platforms
10 May 2022 //
PRNEWSWIRE
Sirnaomics Begins Dosing in Phase I Trial of STP707 for Liver Fibrosis in PSC
04 Apr 2022 //
PRNEWSWIRE
Sirnaomics Announces Interim Data from Phase II Clinical Trial of STP705
22 Feb 2022 //
PRNEWSWIRE
Sirnaomics Receives Safe to Proceed Letter for U.S. FDA IND for STP707 in PSC
16 Feb 2022 //
PRNEWSWIRE
Sirnaomics begins phase I trial of siRNA drug candidate, STP707
10 Feb 2022 //
PHARMABIZ
Sirnaomics the RNA Therapeutics Biopharmaceutical Company
30 Dec 2021 //
PRNEWSWIRE
Sirnaomics to Present STP705, the Company`s Lead Drug Candidate Conference
18 Oct 2021 //
PRNEWSWIRE
Stemson snags $15M series A for hairy brush-up with Rogaine, Propecia
17 Jul 2021 //
FIERCEBIOTECH
Sirnaomics begins patient dosing in phase 2 study of STP705
16 Jul 2021 //
PHARMABIZ
Sirnaomics puts off an IPO a little longer as it pockets another megaround
02 Jul 2021 //
ENDPTS
Sirnaomics nabs a rare series E worth $105M
02 Jul 2021 //
FIERCEBIOTECH
Sirnaomics Secures $105 Million in Series E Financing
01 Jul 2021 //
PR NEWSWIRE
Sirnaomics puts off an IPO a little longer as it pockets another megaround
01 Jul 2021 //
ENDPTS
Sirnaomics Doses First Patient in Phase 2b Study of STP705
30 Jun 2021 //
PR NEWSWIRE
Sirnaomics doses first subject in Phase I liver cancer study
26 Jun 2021 //
CLINICAL TRAILS ARENA
Sirnaomics Doses First Patient in Phase 1 U.S. Clinical Study of STP705
26 Jun 2021 //
PR NEWSWIRE
Sirnaomics Doses First Patient in Phase 1 U.S. Clinical Study of STP705
26 Jun 2021 //
PR NEWSWIRE
Sirnaomics Announces Acceptance of IND Application for Phase 2b Trial of STP705
17 Jun 2021 //
PRNEWSWIRE
